The activity of the mammalian target of rapamycin (mTOR), an ubiquitously expressed serine/threonine kinase, is central to the regulation of translation initiation and, consequently protein synthesis required for long-term potentiation and new synaptic connections. Recent studies show that activation of the mTOR signaling pathway is required for the rapid antidepressant actions of glutamate N-methyl-D-aspartate (NMDA) receptor antagonists such as ketamine. Our prior work documented the first evidence of robust deficits in the mTOR signaling pathway in the prefrontal cortex (PFC) from subjects diagnosed with major depressive disorder (MDD). The goal of this study was to determine whether alterations in mTOR signaling can be observed in rats exposed to the chronic unpredictable stress (CUS) model of depression. In the present study, we examined the effect of CUS on the expression of phosphorylated mTOR and its downstream signaling components in the frontal cortex, hippocampus, amygdala, and dorsal raphe. We also examined the effect of CUS on the expression of kinases that phosphorylate mTOR such as extracellular signal-regulated kinase (ERK1/2) and protein kinase B/Akt (Akt1). In addition, we examined the effect of stress on the phosphorylation of GluR1 an, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunit. We found that eight-weeks of CUS exposure significantly decreased the phosphorylation levels of mTOR and its downstream signaling components in the amygdala. Reduced level of phospho-mTOR in the amygdala was accompanied by decreased phosphorylation of ERK-1/2, Akt-1, and GluR1. No significant changes were seen in the frontal cortex, hippocampus, or dorsal raphe. Our study demonstrates that long-term stress exposure results in brain region-specific abnormalities in signaling pathways previously linked to novel mechanisms for rapid antidepressant effects. These observations are in line with evidence showing that mTOR and its upstream and downstream signaling partners could be important targets for the development of novel antidepressants.
Introduction
Our previous postmortem studies showed robust deficits in the mammalian target of rapamycin (mTOR) signaling in the prefrontal cortex (PFC) of subjects diagnosed with major depressive disorder (MDD). Reduced protein expression of mTOR, and its two major downstream signaling effectors, the 70-kDa ribosomal protein S6 kinase (p70S6K) and eukaryotic translation initiation factor 4B (eIF-4B) has been previously demonstrated (Jernigan et al., 2011) . These results indicate that deficits in mTOR-dependent protein synthesis may contribute to the molecular and cellular pathology detected in the PFC in MDD. Accordingly, deficits in prominent postsynaptic proteins including N-methyl-D-aspartate (NMDA) receptor subunits (NR2A and NR2B), metabotropic glutamate receptor subtype 5 (mGluR5) and postsynaptic density protein 95 kDa (PSD-95) were previously demonstrated in the PFC from depressed subjects (Deschwanden et al., 2011; Feyissa et al., 2009) . Based on these studies, it is tempting to hypothesize that an activation of mTOR function followed by enhanced mTOR-dependent protein synthesis may underlie antidepressant action. In fact, it has been recently demonstrated that a rapid increase in mTOR activity (measured by increased phosphorylation levels) and an induction of synaptogenesis in the rat PFC are responsible for the rapid and sustained antidepressant-like effects of ketamine (an NMDA receptor antagonist) and LY341495 (a metabotropic glutamate receptor subtype 2/3 antagonist) in animal screening procedures (Dwyer et al., 2012; Koike et al., 2011; Li et al., 2010 Li et al., , 2011 reviewed by Hashimoto, 2011) . Moreover,
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